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Background Th is study aimed to assess the endoscopic burden of bariatric surgical procedures 
at our trust. Th is is an enhanced parallel study to “Th e Hidden Endoscopic burden of Roux-en-Y 
Gastric Bypass” published in Frontline Gastroenterology in 2013  incorporating the data for sleeve 
gastrectomy and comparison with Roux-en-Y gastric bypass (RYGB).
Methods Th is is a retrospective study that included 211 patients undergoing sleeve gastrectomy 
over a 34-month period. We utilized previously collected data for the RYGB patient cohort which 
included 553 patients over a 29-month period. We searched our hospital endoscopic database for 
patients who underwent post-operative endoscopy for indications related to their surgery.
Results 16.6% of the sleeve gastrectomy patients required post-operative endoscopy, of whom 
11.4% underwent therapeutic procedures. Th is compares to 20.4% of the RYGB cohort of whom 
50.4% needed therapeutic procedures (P<0.001). 1.9% of sleeve gastrectomy patients encountered 
a post-operative staple line leak and collectively required 29 endoscopic procedures. One patient 
also developed stricturing (0.47%) requiring 18 pneumatic dilatations. 11.4% of the RYGB cohort 
developed an anastomotic stricture requiring 57 balloon dilatation procedures. To date, these 
procedures have accumulated an equivalent cost of €159,898 in endoscopy tariff s, or €177 per 
RYGB and €373 per sleeve gastrectomy performed.
Conclusions Bariatric surgery can have signifi cant implications in terms of patient morbidity 
and fi nancial cost. Having a local bariatric surgery service increases the demand for endoscopic 
procedures in our hospital, both in investigating for and dealing with post-operative complications. 
Provision of extra resources and expertise needs to be taken into account.
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Introduction
Th e UK is encountering an obesity crisis, with 61.9% of 
adults being classifi ed as obese [1]. Obesity-related health 
problems are estimated to cost the NHS the equivalent of 
nearly €7 billion per year [2]. It is estimated that 50% of the 
world’s population will be obese by the year 2030 [3]. In 2008, 
the UK National Institute for Clinical Excellence (NICE) issued 
guidance on the management of obesity. It recommended 
bariatric surgery as an option to patients with a body mass index 
(BMI) of over 40, or between 35 and 40 if they have signifi cant 
co-morbidities that could be improved by losing weight (such 
as type 2 diabetes mellitus). Non-surgical measures should be 
attempted fi rst unless the patient has a BMI of over 50, when 
surgery can be considered as fi rst line. All patients should 
receive intensive management in a specialist obesity center [4].
A number of bariatric surgical options are available, 
including laparoscopic gastric band insertion, Roux-en-Y 
gastric bypass (RYGB) and sleeve gastrectomy. Th e UK’s Walsall 
Manor Hospital is one of the main centers for bariatric surgery 
in the West Midlands. Like all procedures, bariatric surgery 
has a risk of complications such as anastomotic leaks and 
stricture formation. Metanalysis suggests that the leak rate for 
sleeve gastrectomy is around 2.4% [5], whereas the incidence of 
anastomotic stricture formation in RYGB surgery varies widely 
between 0.8% [6] and 23% [7]. Sleeve gastrectomy has been 
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shown to achieve comparable weight loss to RYGB surgery but 
is felt to be a simpler procedure with a lower long-term risk 
profi le and so the number of these procedures in comparison 
to RYGB is increasing [8].
Complications of bariatric surgery are oft en investigated, 
diagnosed and managed by the use of endoscopic procedures, 
such as endoscopic stent insertion for an anastomotic leak, or 
balloon dilatation for a stricture. In 2012 Steed et al showed 
that RYGB surgery had a signifi cant impact on local endoscopic 
services and this was associated with an added cost to the NHS [1].
Th e total number of bariatric surgeries performed in 
the UK is rising. From 2006 to 2012 there was a 530% rise 
in RYGB surgeries performed for obesity in the UK [9]. In 
November 2014, NICE issued new guidance which, for the 
fi rst time, states that patients with a BMI of 30-35 with recent 
onset type 2 diabetes mellitus can be considered for bariatric 
surgery, in particular those of Asian family origin [10]. Given 
the increasing obesity rates and change to NICE guidance, it is 
likely that more bariatric surgery will be performed in the UK 
in the coming years.
Th e aim of this study was to assess the current endoscopic 
burden of bariatric surgery at our center, including RYGB and 
sleeve gastrectomy. Th is is intended to be a sister article to the 
aforementioned article on RYGB surgery and we thank the 
authors for endorsing the use of their data.
Patients and methods
Study design and patient selection
All 553  patients undergoing RYGB between 1st  February 
2008 and 31st July 2010 were included in the original study by 
Steed et al [1]. RYGB procedures were still being performed 
aft er July 2010, however with less frequency given the 
alternative option of sleeve gastrectomy, performed in our trust 
from January 2011. we included all 211  patients undergoing 
sleeve gastrectomy from this date until 2nd October 2013. For 
our study we utilized the previously collected RYGB data and 
added current sleeve gastrectomy data. Th e follow-up period 
was a minimum of 180 days in both groups. All patients were 
retrospectively investigated for post-operative endoscopic 
procedures and, if so, their electronic records were reviewed.
Bariatric surgery
Th e Bariatric Service at Walsall Manor Hospital receives 
referrals according to the NICE guidance criteria. If 
surgical management is decided upon, the type of surgery 
is a combination of surgeon recommendation and patient 
preference. If the patient is on a proton pump inhibitor 
(PPI) or histamine 2 (H2) blocker then further questions are 
asked regarding symptoms of acid refl ux or dyspepsia. If this 
is positive then a pre-operative Barium swallow and meal is 
performed to look for a hiatus hernia and other physical 
abnormalities, which may preclude bariatric surgery or aff ect 
the surgical methods used.
During the sleeve gastrectomy procedures, Endo Gia 
Ultra staples were used and the length of these was graduated 
along the staple line based on the stomach wall thickness, 
with longer staples used towards the antrum in an attempt to 
reduce the risk of a staple-line leak. For the RYGB procedures, 
a 25 mm stapler was used and a 1.5 m Roux loop was made 
for open procedures, with a 45  mm stapler and 1  m Roux 
loop for laparoscopic procedures. All patients underwent 
gastrografi n swallow 24-48 h post-operatively, before oral diet 
was allowed. Th is was to exclude any immediate leaking from 
the anastomosis/staple line which may need urgent return to 
theatre or endoscopic procedures. Th is was done routinely in 
a bid to prevent further complications if we waited until the 
patient’s became symptomatic from any leak. All patients were 
discharged with PPI therapy for life. 
Cost of endoscopy procedures
All procedures have an associated cost, or “tariff ”, to the 
NHS. In 2013, these were the equivalent of €481 for a diagnostic 
gastroscopy, €905 for endoscopic balloon dilatation and €4941 
for an endoscopic stent insertion, including the consumables 
used. In the original Steed et al study, 2010 tariff s were used 
however, for the purposes of comparison in this study; we have 
used 2013 tariff s for both cohorts. Th ese tariff s were gathered 
from the Hospital’s fi nance department.
Statistical analysis
Comparisons between the RYGB and Sleeve Gastrectomy 
eras were made using Fisher’s exact test for nominal factors, and 
Kendall’s Tau for ordinal factors. All analyses were performed 
using IBM SPSS Statistics 22 (IBM Corp. Armonk, NY).
Results
Demographic data
211 patients underwent sleeve gastrectomy in this period, 
35 of whom underwent post-operative upper GI endoscopy 
(16.6%). Th is compares to 20.4% for the Steed Roux-en-Y 
patient data where 113 of the 553 surgical patients required 
post-operative endoscopy (P=0.26).
Overview of endoscopic procedures performed
Th e aforementioned 35 post-sleeve gastrectomy patients had 
66 upper gastrointestinal endoscopies between them. Th e 113 
RYGB patients required 147 procedures. In both groups, 44% 
of the total number of endoscopic procedures were therapeutic 
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while 56% were diagnostic. In the sleeve gastrectomy cohort, 
39.4% of procedures were done as an inpatient compared 
to only 3.4% in the RYGB cohort (P<0.001). Th ere were no 
complications resulting from any of the endoscopic procedures.
Using 2013 endoscopy tariff s, the sleeve gastrectomy cohort 
has totalled the equivalent of €78,736 to date. Th is was €373 
per surgery performed and included €17,781 in diagnostic 
endoscopy, and €60,955 in therapeutic endoscopy. Using the 
same tariff s for the RYGB patients (to aid in comparison), the 
total was €98,248. €39,407 went towards diagnostic gastroscopy, 
and €58,842 towards therapeutic gastroscopy, at a cost of €177 
per RYGB operation performed (€147 if using 2010 tariff s).
Indications for endoscopic procedures
Th e indications for endoscopic procedures are shown in 
Table  1. Th e most common indication for endoscopy in the 
sleeve gastrectomy group was dysphagia (53%), with persistent 
vomiting also being a signifi cant problem (15.2%) followed by 
persistent dyspepsia (13.6%). Th is diff ers from the RYGB data 
whereby dysphagia accounted for 31.3% (P=0.004), persistent 
vomiting for 63.3% (P<0.001) and dyspepsia 2.0% (P=0.002).
Dyspepsia, in particular, was seen more oft en in post-sleeve 
gastrectomy than in post-RYGB surgery. Of the 9 post-sleeve 
gastrectomy patients suff ering with dyspeptic symptoms, 4 
showed esophagitis, 2 gastritis, 2 hiatus hernia, and 1 was normal. 
An additional 11 patients suff ering with other symptoms also 
showed signs of infl ammation and 2 further hiatus hernias were 
found at endoscopy. Th is makes a total of 9% of the total sleeve 
gastrectomy group symptomatic from gastroesophageal refl ux 
disease (GERD). Two post-sleeve gastrectomy patients were 
found to have symptomatic ulceration (0.95% for the whole 
sleeve gastrectomy group) but neither of these patients required 
endoscopic or surgical intervention. Th is compares to 4 of the 
Roux-en-Y patients (0.7%, P=0.67).
Therapeutic endoscopic procedures
Th e 29 post sleeve gastrectomy therapeutic procedures were 
performed on only 4 patients (1.9%), compared to 57 RYGB 
patients who required 63 procedures between them (10.3%, 
P<0.001). Th e 4 sleeve gastrectomy patients who underwent 
therapeutic endoscopy had all suff ered a staple line leak (1.9%). 
One of these patients then developed stricturing post-leak, 
0.47% of the total sleeve gastrectomy group. Th ese 4 patients 
totalled 14 pneumatic dilatations, 9 stent insertions and 
5 naso-jejunal tube insertions. If a therapeutic endoscopy was 
required post sleeve gastrectomy, the numbers ranged from 
2 to 18 procedures per patient.
One sleeve gastrectomy patient had a staple line leak 
followed by stricture formation and has required 18 endoscopic 
procedures to date, including 14 balloon dilatations, 3 stents and 
one nasojejunal tube insertion. Of the total endoscopic bill for 
the sleeve gastrectomy cohort of €78,736, this patient accounts 
for the equivalent of €35,693  (45%), with future procedures 
likely. Th e other 3 patients mentioned only required between 
2 and 6 procedures before remaining asymptomatic for the 
rest of the follow-up period. Th e mean number of therapeutic 
endoscopy procedures needed in the sleeve gastrectomy group 
was 7.25 procedures, with a median of 4 procedures per patient.
Th is compares to 65 therapeutic procedures in the Roux-
en-Y group on 57  patients, all of which were pneumatic 
dilatations due to stricture formation, with no leaks seen. 
An additional 5  patients returned to the operating theater 
due to severe stricturing, all diagnosed via endoscopy. Th is 
gives an overall stricture rate of 11.39% in the RYGB surgery 
group. Patients treated endoscopically required between 
1 and 3 procedures, with a mean of 1.14. Both the rates of 
anastomotic leak and stricture formation were statistically 
signifi cant between the two surgical groups (P<0.05).
All complications needing therapeutic endoscopy were seen 
within 44  days in the sleeve gastrectomy cohort. Th is diff ers 
from the RYGB cohort whereby new strictures were seen up 
to 506  days post-operatively, with 60% seen within the fi rst 
3  months, 95% within 6  months and 5 percent presenting 
between 6 and 17 months [1]. A full comparison of our results 
for the two surgical procedures can be found in Table 2.
Discussion
Th e data we have presented is only for our trust and patients 
may have attended other local endoscopy centers. We did not 
Table 1 Indication for upper gastrointestinal endoscopic procedures (numbers in brackets indicate Roux-en-Y gastric bypass data)









Persistent vomiting 5 (48) 5 (45) 0 (10) 10 (83) 6 (2) 4 (91)
Dysphagia 14 (16) 21 (30) 1 (0) 34 (46) 9 (0) 26 (46)
Hematemesis/melena 0 (0) 2 (4) 0 (1) 2 (3) 0 (3) 2 (1)
Dyspepsia 0 (1) 9 (2) 0 (0) 9 (3) 1 (0) 8 (3)
Abdominal pain 0 (0) 0 (1) 0 (0) 0 (1) 0 (0) 0 (1)
Leak on GG swallow (for stent insertion) 7 (0) 0 (0) 3 (0) 4 (0) 7 (0) 0 (0)
Planned stent removal 3 (0) 0 (0) 0 (0) 3 (0) 3 (0) 0 (0)
GG, gastrografin
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contact patients directly to ask about symptoms or if they 
had attended services elsewhere. Th is may underestimate 
the total endoscopic cost. However, all bariatric patients are 
off ered long-term follow up locally and we assume that most 
patients, especially those who encountered signifi cant post-
operative problems, will have attended our endoscopy unit 
due to our close links with the in-house bariatric service. In 
addition, it is possible that the follow-up period of 180  days 
will have missed some late endoscopic procedures for those 
patients who underwent surgery towards the end of the study 
period. However, all patients requiring therapeutic endoscopy 
post sleeve gastrectomy presented to our unit within 6 weeks 
of their surgery. In contrast, 95% of patients presenting with 
stricturing post-RYGB presented over the longer time scale of 
up to 6 months and so it is therefore possible that our follow-up 
period could have missed some late stricture formation in the 
RYGB cohort.
Overall, there were a large number of diagnostic procedures 
performed to our cohorts which did not lead to endoscopic 
therapy or any other change in management. Th e question 
must be asked whether all of these procedures were truly 
indicated or whether we are currently over-investigating some 
of these patients. Given that further increases in the popularity 
of bariatric surgeries are likely to be seen in the coming years, it 
may benefi t the endoscopy department to formalize a protocol 
as to when/if to perform endoscopy in these patients. Our 
data regarding the likely timing of therapeutic endoscopy, 
depending on the surgical procedures performed, may aid with 
this.
Much of the total endoscopic cost is via therapeutic 
endoscopy with its higher tariff s and increased endoscopist 
expertise required. More of the RYGB cohort required 
therapeutic endoscopy compared to the sleeve gastrectomy 
cohort (P<0.001). However, the RYGB group required fewer 
procedures per patient compared to the sleeve gastrectomy 
patients (P<0.001). All 4 sleeve gastrectomy patients who 
required post-operative therapeutic endoscopy had fi rst 
suff ered a suture line leak, and they required at least 1 stent 
insertion each. Th is procedure has a high tariff  of €4941 and 
this procedure alone accounts for 56% of the endoscopy bill 
in this cohort. Endoscopic stent insertion was successful in 
all these patients, without the need for further surgery. No 
complications were seen, although more than one stent may 
have been required. Th is indicates that stent insertion for 
treatment of a staple line aft er sleeve gastrectomy is costly, but 
safe and eff ective. Aft er the study period ended, changes were 
Table 2 Comparison of Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy data
Parameter RYGB (%) Sleeve gastrectomy (%) P-value
Patients requiring gastroscopy 113/553 (20.4) 35/211 (16.6) 0.260
Type of gastroscopy <0.001*
Th erapeutic 57/113 (50.4) 4/35 (11.4)
Diagnostic 56/113 (49.6) 31/35 (88.6)





Location of endoscopic procedures <0.001*
Inpatient 5/147 (3.4) 26/66 (39.4)
Outpatient 142/147 (96.6) 40/66 (60.6)
Complications of surgery -
Leak 0/553 (0) 4/211 (1.9) 0.006*
Stricture 63/553 (11.4) 1/211 (0.5) <0.001*
Indication for endoscopic procedures <0.001*
Vomiting 93/147 (63.3) 10/66 (15.2) <0.001*
Dysphagia 46/147 (31.3) 35/66 (53.0) 0.004*
Hematemesis/melena 4/147 (2.7) 2/66 (3.0) 1.000
Dyspepsia 3/147 (2.0) 9/66 (13.6) 0.002*
Abdominal pain 1/147 (0.7) 0/66 (0.0) 1.000
Leak on contrast study 0/147 (0.0) 7/66 (10.6) <0.001*
Planned stent removal 0/147 (0.0) 3/66 (4.6) 0.029*
P-values from Fisher’s exact test, unless stated otherwise. #Factor is ordinal, so P value comes from Kendall’s Tau b. *Significant at P<0.05
48 K. Arndtz et al
Annals of Gastroenterology 29 
made locally to reduce the leak rate post sleeve gastrectomy 
by biologically re-enforcing the staple line, as was suggested 
through international consensus [11]. Th is may have reduced 
the need for future patients requiring this surgery to undergo 
therapeutic endoscopy due to leakage, and thus signifi cantly 
reduce the burden on our endoscopy units. However, the 
management of one sleeve gastrectomy patient is ongoing, 
with many more therapeutic endoscopic procedures likely for 
treatment of recurrent post-leak stricturing. No other sleeve 
gastrectomy patient presented with a stricture within the study 
period. Th is patient could be considered an anomaly, however, 
in a group of only 4 post-sleeve gastrectomy therapeutic 
endoscopy patients, more data is needed to ascertain this 
further. No complications were seen from the multiple balloon 
dilatation procedures, except recurrence of symptoms over 
time. Th is indicates that endoscopic treatment of anastomotic 
strictures post sleeve gastrectomy via balloon dilatation is safe 
and provides short-term relief. It can however require repeat 
procedures which come at a signifi cant fi nancial cost and 
patient morbidity.
Our calculations only include the endoscopic tariff s and 
do not take into account other hidden costs such as hospital 
admissions. 39.4% of procedures were done as an inpatient in 
the sleeve gastrectomy cohort compared to 3.4% in the RYGB 
group (P<0.001). Th ese were mostly therapeutic procedures 
aft er experiencing a leak. While this likely has a signifi cant 
added cost in our data set, it may improve with the above-
mentioned changes to surgical practise to reduce the leak rates.
Post-sleeve gastrectomy complications and dyspeptic 
symptoms are more common in patients with pre-operative 
refl ux disease, therefore this is felt to be a relative contra-
indication to sleeve gastrectomy [12]. Th e question remains 
whether routine pre-operative testing of all patients for 
GERD via endoscopy and/or physiological studies should 
be recommended, instead of the barium swallow which 
our department currently utilizes in symptomatic patients. 
Studies so far have shown little benefi t in asymptomatic 
patients but patients with relevant symptoms should be 
screened [13]. Furthermore, large-scale studies are needed 
but it must be remembered that there would be additional 
associated costs that need to be provided for if this were to 
be implemented.
Despite the limitations in our study, this data does show 
the current endoscopic burden of our bariatric service on 
our trust endoscopy unit. We have calculated these costs to 
be, at present, €373 per sleeve gastrectomy procedure and 
€177 per RYGB performed. Th is could be applied to other 
hospitals performing similar procedures and could be used for 
estimating future endoscopic workload that bariatric surgery 
poses to the NHS.
Given the recent changes to NICE guidance, more bariatric 
surgeries are likely to be done over the forthcoming years, 
which can only increase the associated endoscopic costs. Th ere 
may be a case for more detailed pre-operative assessment for 
GERD in some patients, which could also add to the hidden 
costs of bariatric surgery. Data from our study could aid in the 
development of protocols by our endoscopy department for 
the appropriate selection of patients requiring endoscopy post-
bariatric surgery. In addition, specifi c expertise is needed in 
the endoscopy department to accurately, eff ectively and safely 
diagnose and manage post-bariatric surgery complications. 
Overall, one should not forget that bariatric surgery and 
any resulting associated complications come at a price, both 
fi nancial to the NHS but also in terms of quality of life for the 
patient. Th ese hidden costs and need for additional resources 
need to be taken into account when commissioning a new 
bariatric surgery service and also when considering expanding 
an already established service. Th is must all be balanced against 
the risks (and costs) of long-term morbidity and mortality that 
obesity poses to a growing number of the population.
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Summary Box
What is already known:
• Th e numbers of bariatric surgical procedures are 
increasing in the UK due to a rise in obesity levels
• In 2014, NICE guidance reduced the recommended 
body mass index limits for consideration of surgery 
to as low as 30 in some cases and this will likely 
result in a further increase in bariatric surgery 
procedures
• Roux-en-Y gastric bypass (RYGB) carries a 
signifi cant endoscopic burden in investigating for 
and dealing with complications
What the new fi ndings are:
• Sleeve gastrectomy also carries a signifi cant 
endoscopic and cost burden; in our study more so 
per procedure than RYGB
• Gastroesophageal refl ux is a relative 
contraindication for sleeve gastrectomy due to 
signifi cant related post-operative complications 
and persistent symptoms. Th ere may be a case for 
detailed pre-operative assessment, which will, in 
itself, add to the hidden costs of bariatric surgery
• Most anastomotic leaks requiring intervention 
present within 6  weeks of sleeve gastrectomy 
surgery whereas stricturing from RYGB can 
present many months later
• Extraendoscopic resources need to be taken into 
account when commissioning a new bariatric service 
or when expanding an already established one
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